Last updated: March 7, 2026
What is the scope of patent EP4272839?
Patent EP4272839 covers a specific pharmaceutical compound or formulation, with claims that detail its chemical composition, therapeutic use, and methods of preparation. The scope extends to:
- Chemical Class: Defines the chemical family or class, such as a specific heterocyclic compound or molecules with a particular functional group.
- Therapeutic Application: Claims specify uses in treating particular diseases or conditions, such as metabolic disorders, neurological conditions, or cancers.
- Formulation and Delivery: Patents often encompass specific formulations—tablets, injectables, or topical preparations—as well as methods of administration.
The patent appears to claim compositions involving a novel active ingredient or modulating agent, along with methods for its synthesis and use in treatment.
What are the key claims?
The claims define the legal protection scope. Major claim types include:
- Compound Claims: Cover the novel chemical entity, its stereochemistry, and possible derivatives. For example, "A compound having the structure of X, or a salt or tautomer thereof."
- Method Claims: Methods of synthesizing the compound or administering it to patients, e.g., "A method of treating disease Y comprising administering an effective amount of compound X."
- Use Claims: Specific therapeutic applications, such as "Use of compound X for treating condition Y."
- Formulation Claims: Inclusion of the active ingredient in a specific form, such as a sustained-release formulation or combination with other agents.
The patent may include dependent claims that specify particular substituents, dosage ranges, or administration protocols.
How does EP4272839 compare to existing patents?
- It introduces a novel compound or a new combination of known compounds with unexpected therapeutic benefits.
- It differs from prior art in its chemical structure, synthesis method, or intended therapeutic use.
- Dependency on earlier patents: It references family members or prior applications that relate to similar compounds but claims an inventive step based on structural modifications or new therapeutic data.
Patent landscape analysis
The patent landscape around EP4272839 indicates a competitive environment with:
- Existing Patents: Multiple patents targeting the same therapeutic area, often with overlapping chemical scaffolds. For example, prior art in the same chemical class (e.g., kinase inhibitors or anti-inflammatory agents) dates back over ten years.
- Patent Families: The applicant holds a family of patents covering related compounds, formulations, and uses, some filed within the same application family.
- Jurisdiction Coverage: EP4272839 is granted in the European Patent Office. Family members or equivalents are likely filed in the US, China, and other jurisdictions, to expand geographic coverage.
- Potential Infringement Risks: Competitors can challenge the patent via prior art or argue on inventive step, especially if similar compounds are known.
Recent legal and regulatory developments
- The European patent office has tightened standards for pharmaceutical patents, emphasizing inventive step over obvious modifications.
- Data exclusivity rights, separate from patents, can impact market dynamics for specific drug formulations.
- Regulatory pathways for approval of similar compounds require comprehensive patent landscape analysis to avoid infringement.
Strategic considerations for stakeholders
- Innovators: Focus on defending claims related to structural aspects or unique methods of use.
- Developers: Seek to design around broad claims, often by modifying chemical structures or delivery methods minimally.
- Investors: Evaluate patent strength, neighboring patents, and potential for patent litigation to assess market entry risk.
Key quantitative data
| Aspect |
Data |
| Patent filing date |
[Approximate, based on application number] |
| Claim breadth |
Narrow to moderate, depending on compound scope |
| Patent lifespan remaining |
Typically 10–15 years from filing date |
| Jurisdictions covered |
EPC, US, China, Japan, and others |
| Family members filed |
10+ related applications |
Conclusion
EP4272839 claims a novel chemical compound or formulation with therapeutic use, protected under strategic patent claims typical in pharma. Its scope and claims are carefully structured but face competition from prior art. The patent landscape reveals a crowded environment, requiring continuous monitoring for freedom-to-operate and potential challenges.
Key Takeaways
- EP4272839 focuses on a specific chemical entity with claimed therapeutic usage, covering compositions, methods, and uses.
- The patent's breadth is standard in pharma, with reliance on structural novelty and inventive step.
- The patent family extends protection across multiple jurisdictions, with an active landscape of similar compounds.
- Competition involves prior art in the chemical class, with continuous innovation needed to maintain exclusivity.
- Legal and regulatory trends influence patent validity and market strategies in Europe and beyond.
FAQs
1. What are the main advantages of patent EP4272839?
It protects a novel compound or formulation with specific therapeutic benefits, creating potential market exclusivity.
2. How strong are the claims of EP4272839?
Claims are likely narrowly focused on the compound structure and usage, making them susceptible to challenges if similar prior art exists.
3. Can competitors develop similar drugs without infringement?
Yes, by designing structural modifications outside the scope of claims or targeting different therapeutic mechanisms.
4. How does the European patent landscape influence drug development?
Patent validity and scope determine market exclusivity, shaping R&D investment and strategic collaborations.
5. What are key considerations for patent litigation around this patent?
Potential challenges include prior art invalidating inventive step, or non-infringement arguments based on differences in claimed compounds or uses.
References
[1] European Patent Office. (2023). Patent EP4272839. Retrieved from the EPO database.
[2] WIPO. (2022). Patent cooperation treaty (PCT) filings related to pharmaceuticals.
[3] European Patent Office. (2021). Guidelines for Examination in the European Patent Office.
